

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kostenuik et al.

Serial No.: 09/843,221

Filed: April 26, 2001

For: Modulators of Receptors for Parathyroid Hormone and Parathyroid Hormone-Related Protein

Docket No.: A-665B

#8

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 15, 2002.

I hereby state that the substitute paper copy and the substitute computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

  
Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: February 27, 2002


Please send all future correspondence to:

U.S. Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL198797791US

Date of Deposit: February 27, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

S.L. ST. ANDREW  
Printed Name  
Signature



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FLING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/843,221	04/26/2001	Paul Kostenuik	A-665B

 21069  
 AMGEN INCORPORATED  
 MAIL STOP 27-4-A  
 ONE AMGEN CENTER DRIVE  
 THOUSAND OAKS, CA 91320-1799

CONFIRMATION NO. 8369

## FORMALITIES LETTER



\*OC00000007311106\*

Date Mailed: 01/15/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE